Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Pembrolizumab vs Chemotherapy in MSI-H/dMMR Stage IV Colorectal Cancer
2015-002024-89Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Pembrolizumab monotherapy with Standard-of-care chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2015-002024-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002024-89.